Champions Oncology (CSBR) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Champions Oncology (CSBR) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Champions Oncology |
81.79 Mn |
74.79 Mn |
13.89 Mn |
-106.21% |
| Date | Value |
|---|
| Jan 31, 2026 |
-106.21% |
| Oct 31, 2025 |
-67.45% |
| Jul 31, 2025 |
-135.49% |
| Apr 30, 2025 |
-1,583.49% |
| Jan 31, 2025 |
277.67% |
| Oct 31, 2024 |
135.15% |
| Jul 31, 2024 |
151.17% |
| Apr 30, 2024 |
95.74% |
| Jan 31, 2024 |
-3.73% |
| Oct 31, 2023 |
-12,843.75% |
| Jul 31, 2023 |
-704.39% |
| Apr 30, 2023 |
-644.48% |
| Jan 31, 2023 |
-409.91% |
| Oct 31, 2022 |
-105.78% |
| Jul 31, 2022 |
-85.47% |
| Apr 30, 2022 |
48.89% |
| Jan 31, 2022 |
-17.94% |
| Oct 31, 2021 |
27,600.00% |
| Jul 31, 2021 |
-329.33% |
| Apr 30, 2021 |
68.91% |
